Broad formulary access means NovoLog® can reach more lives.1 NovoLog® FlexPen® and vials are on Tier 2, with the lowest branded copay, for more than 85% of managed care patients nationwide.1*
NovoLog® makes analog insulin accessible1
NovoLog® is covered for more than 85% of managed care patients nationwide.a,b
Help your patients calculate their individual co-pay in a few short steps with this convenient tool.
Lowest branded co-pay for your Medicare Part D patients1 nationwideb
NovoLog® formulary status at top commercial health care and Medicare Part D plans is comparable to regular human insulin.c
a Managed care plans only. Does not include Medicaid and Medicaid Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status is subject to change. Multiple products within the same therapeutic class may be considered preferred and on the same tier.
b Formulary data are provided by Fingertip Formulary® and are current as of [February 2013]. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. ® 2013 Fingertip Formulary. All rights reserved.
c Regular human insulin is not a generic. No generic insulins are available in the United States.
More units. Same co-pay
One box of NovoLog® FlexPen® provides 50% more insulin than a vial for the same co-pay on most managed care plans
9 out of 10 physicians say it is important to minimize patients’ out-of-pocket costs when prescribing2